Summary:
Study H8H-MC-LAHV (Study LAHV) will enable a clinical assessment of lasmiditan in a pediatric patient population with migraine for which the medical need is substantial. This study is part of a pediatric clinical program that is intended to provide pivotal efficacy and safety data to support use of lasmiditan for acute treatment of migraine in pediatric patients.
Qualified Participants Must:
• 6-17 years old
•
History of migraine attacks for more than 6 months lasting for at least 2 hours
Qualified Participants May Receive:
-No Cost Investigational Medication
-No Cost Study-Related Docotor Visits
-Compensation For Time and Travel